Organogenesis (NASDAQ:ORGO) Trading Down 2.1% – What’s Next?

Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) traded down 2.1% on Friday . The company traded as low as $5.10 and last traded at $5.14. 220,836 shares were traded during mid-day trading, a decline of 79% from the average session volume of 1,071,226 shares. The stock had previously closed at $5.25.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley boosted their target price on Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th.

Organogenesis Price Performance

The firm has a market cap of $650.12 million, a P/E ratio of -85.42 and a beta of 1.66. The stock’s 50-day simple moving average is $3.82 and its two-hundred day simple moving average is $3.41. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Insiders Place Their Bets

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares in the company, valued at approximately $851,082.90. This represents a 13.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 36.90% of the company’s stock.

Institutional Trading of Organogenesis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its stake in Organogenesis by 54.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after purchasing an additional 1,035,120 shares during the last quarter. Soleus Capital Management L.P. grew its stake in shares of Organogenesis by 5.4% during the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock worth $39,952,000 after purchasing an additional 645,000 shares during the period. Norges Bank purchased a new stake in shares of Organogenesis in the 4th quarter worth about $1,543,000. Dimensional Fund Advisors LP lifted its holdings in Organogenesis by 18.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock valued at $8,925,000 after purchasing an additional 442,772 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Organogenesis by 31.3% during the fourth quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company’s stock worth $3,435,000 after buying an additional 255,600 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.